Overactive Bladder Persisting After Combination Pharmacotherapy: Next-Line Procedural Management
When pharmacological management of overactive bladder — including switching medications or advancing to combination regimens — fails to adequately reduce symptoms, a structured next-line approach is indicated. This protocol addresses that specific clinical situation.
Previous Treatment — Goals Not Achieved
The prior line involved switching to a different medication or using combination pharmacotherapy. The clinical goals of improving incontinence episodes and micturition frequency were not sufficiently met, triggering escalation to this protocol.
Next-Step Approach
For patients who have not responded adequately to pharmacotherapy, this protocol moves to a minimally invasive procedural intervention. The specific procedure options and the criteria for selecting among them are outlined in the full structured regimen.
Clinical Goals
Reduction in urgency urinary incontinence episodes and urinary frequency.
References
DOI: 10.1097/JU.0000000000003985
In patients with OAB who have an inadequate response to, or have experienced intolerable side effects from, pharmacotherapy or behavioral therapy, clinicians should offer sacral neuromodulation, percutaneous tibial nerve stimulation, and/or intradetrusor botulinum toxin injection.
Of note, the recommended starting dose for idiopathic OAB is 100U.
Men and women with inadequate response to BTX 100U and minimal side effects may be offered BTX 200U, but should be monitored for and counseled regarding the potential for increased risk for adverse effects such as incomplete bladder emptying requiring CIC and UTI.
View source ↗